Mediwhale

Executive Summary

Mediwhale is a Singapore-based AI medtech company pioneering the use of retinal imaging for non-invasive cardiovascular and cardiometabolic risk assessment. Its flagship products, Dr. Noon CVD and Dr. Noon Fundus, leverage deep-learning algorithms to deliver rapid, radiation-free predictions of heart disease, stroke, and diabetic eye complications. Founded in 2020, the company has scaled to 50–200 employees and reached commercial stage, indicating market traction. By enabling early preventive care across multiple organ systems (heart, kidney, liver, neurology), Mediwhale addresses a critical gap in primary care and population health screening. The platform's ability to extract systemic biomarkers from a simple retinal scan positions it as a cost-effective triage tool that could reduce global healthcare costs and improve outcomes in chronic disease management. The company currently operates primarily in Asia but has expansion ambitions into the US and European markets.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) clearance for Dr. Noon CVD in the US market65% success
• Q2 2027Partnership with a major US health system or insurance provider for pilot deployment60% success
• Q4 2026Publication of large-scale validation study in a top-tier medical journal70% success